Xbrane Biopharma and Biogen have struck a global licensing and commercialization deal for Xbrane’s Xcimzane (certolizumab pegol) proposed biosimilar rival to Cimzia that is currently at the pre-clinical stage. Through the agreement, Biogen will gain exclusive global regulatory, manufacturing and commercial rights to Xcimzane and will be the marketing authorization holder for the biosimilar.
As part of the transaction, Biogen has agreed to make an upfront payment of $8m to Xbrane, along with a...
